SCHEMBL2021602

SCHEMBL2021602

Cc1cccc(C)c1-c1ccc(O[Si](C)(C)C(C)(C)C)c(COc2ccc(/C=N/O)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 9/20 0.48
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
MAPT P10636 3/20 0.41
HPGD P15428 1/20 0.41
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
RAD52 P43351 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2021604 1.00 FFAR1 (0.48) FFAR1NPC1RAB9ASMN1; SMN2CASP3
SCHEMBL2022392 0.82 FFAR1 (0.53) FFAR1FFAR4
SCHEMBL2020335 0.77 FFAR1 (0.39) FFAR1
SCHEMBL4024641 0.69 KMT2A (0.49) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL4024645 0.69 KMT2A (0.49) NPC1RAB9ASMN1; SMN2CASP3SENP8
SCHEMBL12577899 0.67 FFAR1 (0.48) FFAR1RAB9A
SCHEMBL12578020 0.66 FFAR1 (0.47) FFAR1RAB9ASMN1; SMN2KDM4E
SCHEMBL12577995 0.66 FFAR1 (0.47) FFAR1RAB9AHPGDMEN1KMT2A
SCHEMBL1747370 0.65 FFAR1 (1.00) FFAR1FFAR4
SCHEMBL26977769 0.65 ALDH1A1 (0.56) NPC1RAB9ASMN1; SMN2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
EP-2011788-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186909-A1 Oxadiazolidinedione Compound GPR119, GPR39, GPR65 FFAR1 64/4885NPC1 1958/4885RAB9A 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.